James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, and the National Institute on Ageing, National Institutes of Health Clinical Research Branch, Baltimore, MD, USA.
BJU Int. 2010 Jul;106(1):28-31. doi: 10.1111/j.1464-410X.2009.09109.x. Epub 2010 Jan 6.
Aetiology (inception cohort) Level of Evidence 2b.
To determine whether there might be differences in bone mineral content (BMC) between men who develop life-threatening prostate cancer and those who do not, as bone is a common site of prostate cancer metastases.
From 1973 to 1984, BMC was serially measured in 519 participants (778 observations) as part of a longitudinal study of ageing. We examined the association between serial BMC measurements with the development of overall and high-risk prostate cancer over the next one to three decades. For all prostate cancer cases, BMC was censored at the time of diagnosis.
During a median (range) overall follow-up of 21.1 (0.2-35.0) years after the last BMC measurement, 76 (14.6%) men were later diagnosed with prostate cancer (18 high-risk and 58 not high-risk). BMC declined with age to a greater extent in healthy controls than among men diagnosed with prostate cancer (P = 0.018, likelihood ratio test), and tended to decline less in high-risk than non-high-risk cases.
The distribution of BMC was significantly different between men who did and did not develop prostate cancer, over an extended follow-up. Specifically, BMC appeared to decline to a greater extent with age among healthy controls than in men with prostate cancer, especially high-risk disease. The biology underlying the lesser decline in BMC among men with prostate cancer remains unclear, but suggests that host factors in the bony milieu might be associated with prostate cancer development and progression.
病因学（起始队列）证据水平 2b。
确定在发生危及生命的前列腺癌和未发生前列腺癌的男性之间，骨矿物质含量（BMC）是否存在差异，因为骨骼是前列腺癌转移的常见部位。
1973 年至 1984 年，作为一项衰老纵向研究的一部分，对 519 名参与者（778 次观察）进行了 BMC 的连续测量。我们检查了 BMC 连续测量与未来一到三十年总体和高危前列腺癌发展之间的关联。对于所有前列腺癌病例，在诊断时对 BMC 进行了删失。
在最后一次 BMC 测量后的中位（范围）总体随访 21.1（0.2-35.0）年后，76 名（14.6%）男性随后被诊断为前列腺癌（18 例高危和 58 例非高危）。与健康对照组相比，在被诊断患有前列腺癌的男性中，BMC 随年龄的下降幅度更大（P = 0.018，似然比检验），并且在高危病例中下降幅度较小。
在延长的随访中，患有和未患有前列腺癌的男性之间的 BMC 分布存在显著差异。具体来说，与患有前列腺癌的男性相比，BMC 在健康对照组中随年龄的下降幅度更大，尤其是高危疾病。在患有前列腺癌的男性中 BMC 下降幅度较小的潜在生物学机制尚不清楚，但表明骨环境中的宿主因素可能与前列腺癌的发生和进展有关。
